O le pathophysiology o le kanesa o le māmā e faasino atu i suiga i faiga masani ma faiga e tutupu i le atinaʻe ma le alualu i luma o le kanesa o le māmā.
O le kanesa o le māmā o se maʻi e faigatā ona togafitia, e māfua mai i le lē pulea o le tupu aʻe ma le vaevaeina o sela e lē masani ai i le māmā.
O nei sela e mafai ona avea ma tuma ma sosolo atu i isi vaega o le tino, ma oo ai i āuga eseese ma faafitauli.
O le pathophysiology o le kanesa o le māmā e aofia ai ni vala eseese, e aofia ai suiga i le sela, o vala o le siʻosiʻomaga, ma filifiliga o le olaga.
E mafai ona iai ni suiga i sela o le DNA o sela o le māmā, ma iʻu ai ina lē pulea le tuputupu aʻe ma le vaevaeina o sela.
E mafai ona tuufaasolo mai pe maua mai i le tino, ma e mafai ona māfua mai i le aafia i mea e māfua ai le kanesa, e pei o le asu o le tapaa, le radon, asbestos, ma le ʻea ua faaleagaina.
E lua ituaiga o kanesa o le māmā: o le kanesa o le māmā e iai sela ninii (SCLC) ma le kanesa e leai ni sela ninii (NSCLC).
E eseese lava le pathophysiology o nei ituaiga o kanesa o le māmā, ona e eseese o latou gene mutations ma e ese foʻi le tali atu i togafitiga.
O le pathophysiology o le kanesa o le māmā e aofia ai foʻi le fesootaʻiga i le va o sela o le kanesa ma isi sela o loo siʻomia ai, e aofia ai ma le vaega e puipuia ai le tino.
E mafai e sela o le kanesa ona ʻalofia le faiga e puipuia ai le tino mai i faamaʻi, ma mafai ai ona tuputupu aʻe ma sosolo atu e aunoa ma se mea e taofia ai.
E lē gata i lea, o le siʻosiʻomaga o le tuma e mafai ona faatupuina ai le tupu aʻe o le tuma ma le metastasis e ala i le saunia o se siʻosiʻomaga e lagolagoina ai sela o le kanesa.
O le pathophysiology o le kanesa o le mama o se faagasologa faigata ma malosi, ma o loo faaauau pea ona galulue tagata suʻesuʻe e malamalama lelei i auala e maua ai togafitiga e sili atu ona lelei ma faaleleia ai taunuuga o tagata gasegase.
Li Z, Qian Y, Li W, Liu L, Yu L, Liu X, Wu G, Wang Y, Luo W, Fang F, Liu Y, Song F, Cai Z, Chen W, Huang W: Human Lung Adenocarcinoma-Derived Organoid Models for Drug Screening. iScience. 2020, 23 (8): 101411.
Nurwidya F, Syahruddin E, Yunus F: Pain management in lung cancer. Adv Respir Med. 2016, 84 (6): 331-336.
Khan KA, Kennedy MP, Moore E, Crush L, Prendeville S, Maher MM, Burke L, Henry MT: Radiological characteristics, histological features and clinical outcomes of lung cancer patients with coexistent idiopathic pulmonary fibrosis. Lung. 2015, 193 (1): 71-7.
Paramanantham A, Asfiya R, Das S, McCully G, Srivastava A: Extracellular Vesicle (EVs) Associated Non-Coding RNAs in Lung Cancer and Therapeutics. Int J Mol Sci. 2022, 23 (21): .
Lee D, Kim Y, Chung C: Scientific Validation and Clinical Application of Lung Cancer Organoids. Cells. 2021, 10 (11): .
Mucchietto V, Crespi A, Fasoli F, Clementi F, Gotti C: Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment. Curr Pharm Des. 2016, 22 (14): 2160-9.
['Faamatalaga: faafomaʻi']
['O lenei upega tafaʻilagi ua saunia mo na o le aʻoaʻoina ma le faailoaina atu o faamatalaga, ae e lē o se fautuaga faafomaʻi po o se auaunaga faapolofesa.']
['E lē tatau ona faaaogā faamatalaga o loo maua mai ai e iloa ai po o le ā le maʻi o loo aafia ai, ma e tatau i ē o loo saʻili mo ni fautuaga faafomaʻi, ona talanoa atu i se fomaʻi ua agavaa.']
['Faamolemole ia mātau, o le neural net lea e maua ai tali i fesili, e lē saʻo pe a oo i fuainumera.']
["Ia saʻili i taimi uma le fautuaga a lau fomaʻi poʻo se isi fomaʻi agavaa e tusa ai ma se maʻi. Aua neʻi e le amanaʻia fautuaga faʻapitoa a fomaʻi pe tuai ona saili ona o se mea na e faitauina i luga o lenei upega tafailagi. Afai e te manatu e ono i ai sau faʻalavelave faʻafuaseʻi, valaʻau le 911 pe alu i le potu lata ane faʻafuaseʻi. E leai se fomaʻi-tagata gasegase sootaga e faia e lenei 'upega tafaʻilagi poʻo lona faʻaaogaina. E leai se BioMedLib poʻo ana tagata faigaluega, poʻo se tasi e fesoasoani i lenei' upega tafaʻilagi, faia ni faʻamatalaga, faʻaalia pe faʻaalia, e tusa ai ma faʻamatalaga o loʻo tuʻuina atu iinei poʻo lona faʻaaogaina."]
['Faʻasalaga: puletaofia']
['O le Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (le DMCA) e maua ai le avanoa mo tagata e umia le puletaofia o loʻo talitonu o mea o loʻo aliali mai i luga o le Initaneti e solia ai a latou aia tatau i lalo o le tulafono a le US copyright. ']
['Afai e te talitonu ma le talitonuga lelei e faapea o so o se mataupu po o meafaitino ua maua e fesootai ma lo tatou website po o auaunaga solia lou puletaofia, e mafai ona e (po o lou sooupu) auina atu i tatou se faasilasilaga talosagaina e faapea o le mataupu po o meafaitino e aveesea, po o le avanoa i ai poloka. ']
['E tatau ona auina atu faasilasilaga i se faiga tusitusia e ala i imeli (tagai i le vaega o le "Contact" mo le tuatusi imeli). ']
['O le DMCA e manaʻomia ai lau faʻasilasilaga o le faʻaleagaina o le puletaofia e aofia ai faʻamatalaga nei: (1) faʻamatalaga o le galuega faʻatagaina o loʻo faʻatatau i le faʻaleagaina o le puletaofia; (2) faʻamatalaga o le mea e ono solia ai ma faʻamatalaga lava e faʻatagaina ai matou ona maua le anotusi; (3) faʻamatalaga faʻafesoʻotaʻi mo oe, e aofia ai lau tuatusi, numera telefoni ma tuatusi imeli; (4) o se faʻamatalaga mai ia te oe o loʻo ia te oe le talitonuga lelei o le anotusi i le auala na faitio ai e le faʻatagaina e le pule o le puletaofia, poʻo lana sooupu, poʻo le faʻatinoina o soʻo se tulafono; ']
['(5) o se faamatalaga mai iā te oe, ua sainia i lalo o le faasalaga o le pepelo, e faapea o faamatalaga o loo i le faasilasilaga e saʻo ma e iai lau pule e faamalosia ai le aiā tatau lea o loo faapea mai ua solia; ']
['ma le (6) saini faaletino po o saini faaeletoroni a lē e ana le aiā tatau po o se tagata ua faatagaina e galue e fai ma sui o lē e ana le aiā tatau. ']
['Afai e lē o aofia uma faamatalaga o loo i luga, e ono faatuai ai ona iloilo lau faitioga.']
['Faafesootaʻi']
['Faamolemole lafo mai se imeli i so o se fesili / fautuaga.']
What is pathophysiology of lung cancer?
The pathophysiology of lung cancer refers to the changes in the normal physiological processes and mechanisms that occur in the development and progression of lung cancer.
Lung cancer is a complex disease that arises from the uncontrolled growth and division of abnormal cells in the lungs.
These cells can form tumors and spread to other parts of the body, leading to various symptoms and complications.
The pathophysiology of lung cancer involves several factors, including genetic mutations, environmental factors, and lifestyle choices.
Genetic mutations can occur in the DNA of lung cells, leading to uncontrolled cell growth and division.
These mutations can be inherited or acquired, and they can be caused by exposure to carcinogens, such as tobacco smoke, radon, asbestos, and air pollution.
Lung cancer can be classified into two main types: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). NSCLC is further divided into three subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.
The pathophysiology of these types of lung cancer can differ, as they have different genetic mutations and respond differently to treatment.
The pathophysiology of lung cancer also involves the interaction between cancer cells and the surrounding tissue, including the immune system.
Cancer cells can evade the immune system, allowing them to grow and spread unchecked.
Additionally, the tumor microenvironment can promote tumor growth and metastasis by providing a supportive environment for cancer cells.
The pathophysiology of lung cancer is a complex and dynamic process, and researchers are continuously working to better understand the underlying mechanisms to develop more effective treatments and improve patient outcomes.
Disclaimer: medical
This web site is provided for educational and informational purposes only and does not constitute providing medical advice or professional services.
The information provided should not be used for diagnosing or treating a health problem or disease, and those seeking personal medical advice should consult with a licensed physician.
Please note the neural net that generates answers to the questions, is specially inaccurate when it comes to numeric content. For example, the number of people diagnosed with a specific disease.
Always seek the advice of your doctor or other qualified health provider regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. If you think you may have a medical emergency, call 911 or go to the nearest emergency room immediately. No physician-patient relationship is created by this web site or its use. Neither BioMedLib nor its employees, nor any contributor to this web site, makes any representations, express or implied, with respect to the information provided herein or to its use.
Disclaimer: copyright
The Digital Millennium Copyright Act of 1998, 17 U.S.C. § 512 (the “DMCA”) provides recourse for copyright owners who believe that material appearing on the Internet infringes their rights under U.S. copyright law. If you believe in good faith that any content or material made available in connection with our website or services infringes your copyright, you (or your agent) may send us a notice requesting that the content or material be removed, or access to it blocked. Notices must be sent in writing by email (see 'Contact' section for email address) . The DMCA requires that your notice of alleged copyright infringement include the following information: (1) description of the copyrighted work that is the subject of claimed infringement; (2) description of the alleged infringing content and information sufficient to permit us to locate the content; (3) contact information for you, including your address, telephone number and email address; (4) a statement by you that you have a good faith belief that the content in the manner complained of is not authorized by the copyright owner, or its agent, or by the operation of any law; (5) a statement by you, signed under penalty of perjury, that the information in the notification is accurate and that you have the authority to enforce the copyrights that are claimed to be infringed; and (6) a physical or electronic signature of the copyright owner or a person authorized to act on the copyright owner’s behalf. Failure to include all of the above information may result in the delay of the processing of your complaint.
['E tusa o le']
['E faaaogā e le BioMedLib ni komepiuta (machine-learning algorithms) e faia ai ni fesili ma ni tali.']
['E amata i le 35 miliona lomiga faafomaʻi o le PubMed/Medline.']
['Tagaʻi i le "Faamatalaga" ma le "Faamatalaga".']
